Understanding Arthritis: A deep dive into causes, types, and home remedies
Arthritis, a term that encompasses over a hundred different conditions affecting joints and connective tissues, presents a significant health challenge across the globe. Characterized by ... Read More
FDA approves biosimilar SIMLANDI by Alvotech and Teva Pharmaceuticals
Alvotech and Teva Pharmaceuticals have achieved a significant milestone with the U.S. Food and Drug Administration's (FDA) approval of SIMLANDI (adalimumab-ryvk) injection. This approval positions ... Read More
Takeda’s TAK-279 meets primary endpoint in Phase 2b trial for psoriatic arthritis
Takeda Pharmaceutical Company announced positive results from its Phase 2b clinical trial for TAK-279, an investigational oral TYK2 inhibitor for treating psoriatic arthritis. Meeting its ... Read More
Home remedies for Arthritis: Natural ways to manage joint inflammation
Arthritis, characterized by joint inflammation, can cause immense pain and restrict physical movements, leading to frustration for those affected. However, there are several home remedies ... Read More
Lupin launches generic version of arthritis drug PENNSAID in US
Lupin Limited has announced the US launch of authorized generic version of Horizon Pharma Therapeutics’ PENNSAID (Diclofenac Sodium Topical Solution), 2% w/w. Diclofenac Sodium Topical ... Read More
Lupin secures Health Canada approval for Enbrel biosimilar – Rymti
Lupin Limited has secured approval from Health Canada for Rymti, the company’s biosimilar to Enbrel (etanercept), an inhibitor of tumour necrosis factor (TNF). Rymti is ... Read More
Bio-Thera, Hikma Pharmaceuticals sign $150m licensing deal for BAT2206
Chinese biopharma company Bio-Thera Solutions has signed a commercialization and license deal worth up to $150 million with Hikma Pharmaceuticals to commercialize the former’s BAT2206. ... Read More
Dr. Reddy’s Laboratories relaunches OTC Naproxen Sodium Tablets in US
Dr. Reddy’s Laboratories said that it has relaunched over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, the store-brand equivalent of Bayer HealthCare’s Aleve, in the ... Read More
AbbVie reports positive results for RINVOQ in SELECT-CHOICE phase 3 trial
AbbVie said that RINVOQ (upadacitinib, 15 mg, once daily) has met the primary endpoint and key secondary endpoints in the SELECT-CHOICE phase 3 trial in ... Read More
Antibe Therapeutics completes patient enrollment in OA knee pain trial for ATB-346
Antibe Therapeutics, a Canadian pharma company has completed enrollment of patients in a phase 2B dose-ranging, efficacy clinical trial of its lead drug candidate ATB-346 ... Read More